\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes New European BauhausThe European Commission has recently published a roadmap for the New European Bauhaus (NEB) Facility which will give direction to the implementation of the New European Bauhaus initiative.
The NEB Facility is a new funding tool of the European Commission for the New European Bauhaus initiative and consists of two parts:
The NEB Facility roadmap is based on the public consultation with the Member States and stakeholders conducted by the European Commission in 2024. This roadmap includes details on the governance structures, budget requirements, potential synergies with other EU programmes and key measures to be undertaken in the implementation of the New European Bauhaus initiative.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Agro-Food, Environment Joint Research Center
The Joint Research Centre (JRC) of the Commission invites applications for hands-on training at its state-of-the-art Nanobiotechnology Laboratory. This call offers researchers the opportunity to strengthen expertise in nanomaterials, nanomedicines, advanced materials, and micro(nano)plastics, with a focus on their detection, characterisation, and i... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
